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A B S T R A C T
Direct-acting antivirals (DAAs) targeting NS5A are broadly effective against hepatitis C virus (HCV) infections,
but sustained virological response rates are generally lower in patients infected with genotype (gt)-1a than gt-1b
viruses. The explanation for this remains uncertain. Here, we adopted a highly accurate, ultra-deep primer ID
sequencing approach to intensively study serial changes in the NS5A-coding region of HCV in gt-1a- and gt-1b-
infected subjects receiving a short course of monotherapy with the NS5A inhibitor, elbasvir. Low or undetectable
levels of viremia precluded on-treatment analysis in gt-1b-infected subjects, but variants with the resistance-
associated substitution (RAS) Y93H in NS5A dominated rebounding virus populations following cessation of
treatment. These variants persisted until the end of the study, two months later. In contrast, while Y93H emerged
in multiple lineages and became dominant in subjects with gt-1a virus, these haplotypes rapidly decreased in
frequency off therapy. Substitutions at Q30 and L31 emerged in distinctly independent lineages at later time
points, ultimately coming to dominate the virus population off therapy. Consistent with this, cell culture studies
with gt-1a and gt-1b reporter viruses and replicons demonstrated that Y93H confers a much greater loss of
replicative fitness in gt-1a than gt-1b virus, and that L31M/V both compensates for the loss of fitness associated
with Q30R (but not Y93H) and also boosts drug resistance. These observations show how differences in the
impact of RASs on drug resistance and replicative fitness influence the evolution of gt-1a and gt-1b viruses
during monotherapy with an antiviral targeting NS5A.
1. Introduction
New all-oral, combination direct-acting antiviral (DAA) therapies
are highly effective against hepatitis C virus (HCV) and result in sus-
tained virological response (SVR) in most (> 95%) persons with
chronic hepatitis C (Bartenschlager et al., 2013). Most DAA combina-
tions used today include an inhibitor of the nonstructural (NS) 5A
protein combined with an NS3/4A protease inhibitor and/or an NS5B
RNA-dependent RNA polymerase inhibitor. While treatment failure is
uncommon, sequencing of HCV RNA after failure typically suggests the
presence of drug-resistant viral variants in patients who do not achieve
SVR. NS5A inhibitors are a highly potent class of DAA (Gao et al., 2010;
Ivanenkov et al., 2017). NS5A is unique to HCV and closely related
viruses with multiple essential functions during the viral life cycle, but
no known enzymatic activity (Ross-Thriepland and Harris, 2015). NS5A
inhibitors have dual modes of action, both impeding viral RNA synth-
esis by blocking the formation of replicase complexes, and also pre-
venting the intracellular assembly of infectious virions (Benzine et al.,
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The Illumina bcl2fastq pipeline (v 1.8.4) was used for initial de-
multiplexing of the data and TCS pipeline (v 1.3.2) to create primer ID
template consensus sequences (TCSs) (available at https://github.com/
SwanstromLab/PID). In-house scripts were generated to derive abun-
dances of substitutions at each nucleotide and amino acid position in
each sample. The primer ID approach allowed identified linkages
within each TCS, and neighbor-joining trees were built with MUSCLE (v
3.8.31) (Edgar, 2004a; b).
2.3. In vitro replicative fitness assays
The impact of RASs on replicative fitness and drug resistance were
determined using recombinant cell culture-adapted gt-1a H77S.3/
GLuc2A (Shimakami et al., 2011) and gt-1b N.2/Gluc2A (Yamane et al.,
2014) reporter viruses expressing Gaussia princeps luciferase (GLuc).
RASs were introduced into plasmid DNAs using Quikchange XL site-
directed mutagenesis (Agilent). Plasmids were linearized with XbaI and
transcribed in vitro to produce HCV genomic RNA with the T7 Mega-
script kit (Ambion, Austin, TX). Huh7 2-3c cells were electroporated
with the RNA and replication fitness assessed by monitoring secreted
GLuc activity as described previously (Mauger et al., 2015; Shimakami
et al., 2011).
3. Results
3.1. Primer ID MiSeq sequencing of HCV RNA in serial plasma samples
Approximately 3000 to 12,000 TCSs were obtained from each
clinical sample, providing a sampling depth of 0.1%–0.03% (defined as
the abundance of minor variants with a 95% chance of being detected)
(Table S1). However, extremely low or undetectable levels of viremia
precluded sequencing of virus in samples collected between 1 and 13
days after starting elbasvir therapy in all gt-1b and some gt-1a-infected
subjects.
3.2. Pre-therapy resistance-associated substitutions and intra-host diversity
We considered that differences in the genetic diversity of gt-1a and
gt-1b viruses could contribute to differences in the development of
NS5A inhibitor resistance and thus treatment outcome. We thus ex-
amined the frequency of pre-treatment polymorphisms at the most re-
levant 16 amino acid positions between codons 23 and 123 of NS5A
(Fig. 1A). Significant baseline intra- and inter-host variation existed at
codons 28, 30 and 93 (positions of several important RASs), but the
intra-host average pairwise diversity (π) of the baseline nucleotide se-
quences of the viral populations did not differ significantly between gt-
1a and gt-1b subjects (π=0.87 vs. 0.82, p=0.30). We also calculated
estimated genetic distances using the model-based Tamura-Nei method
(TN93 distance) which assesses the distribution of pairwise distances
between sequences (Tamura and Nei, 1993). Three of 7 gt-1a subjects
(subjects 1, 2, and 5) but only 1 of 6 gt-1b subjects (subject 12) showed
a high frequency of TCSs with a TN93 distance greater than 0.04 sub-
stitutions/site (p=0.24 by χ2 test) (Fig. 1B and C). The existence of
multiple peaks in the frequency distributions of TN93 distance suggest
that these subjects had several distinct viral lineages before therapy.
3.3. Elbasvir-induced changes in sequence encoding NS5A domain I
We calculated Shannon's entropy as a measure of the variability of
amino acid residues at each position within the NS5A protein (Korber
et al., 1994). Significant elbasvir-induced changes occurred between
baseline and day 28 in gt-1a virus infected subjects at codons 28, 30,
31, 58, and 93 (Fig. S1), and in gt-1b subjects at codons 28, 31, and 93
(Fig. S2). Significant changes in the frequency of amino acid poly-
morphisms were evident by day 1, but not 4hr after the start of elbasvir
therapy. In contrast, no changes were observed in Shannon's entropy at
any position in subjects (7 and 13) receiving placebo.
2017; Berger et al., 2014; Boson et al., 2017; McGivern et al., 2014).
HCV is characterized by a high degree of inter- and intra-host di-
versity, which likely plays an important role in the response to DAAs 
and development of resistance (Jabara et al., 2014; Smith et al., 2014). 
There are 7 HCV genotypes that differ by more than 30% at the nu-
cleotide level, with each further divided into subtypes that differ by 
20% (Smith et al., 2014). Genotype 1 (gt-1) is the most common 
globally and in the U.S. Early phase 1 clinical trials of NS5A inhibitors 
suggested that the antiviral efficacy of NS5A inhibitors was greater in 
patients with gt-1b versus gt-1a infection (Lawitz et al., 2012; Liu et al., 
2015). Amino acid substitutions in NS5A associated with antiviral re-
sistance (‘resistance-associated substitutions’ or RASs) also differ be-
tween gt-1a and gt-1b viruses (Issur and Gotte, 2014; Lontok et al., 
2015; Zeuzem et al., 2017). Amino acid substitutions conferring at least 
a 2.5-fold reduction in susceptibility to an NS5A inhibitor (daclatasvir, 
ledipasvir, pibrentasvir, or elbasvir) have been identified at residues 24, 
28, 30, 31, 32, 38, 58, 92, and 93 within domain I of NS5A (Gottwein 
et al., 2018; HCV Drug Development Advisory Group, 2012; Zeuzem 
et al., 2017). However, the diversity of RASs appears to be greater in gt-
1a than gt-1b viruses (Zeuzem et al., 2017). More importantly, while 
pre-existing NS5A RASs may negatively impact the SVR rate in gt-1a 
patients treated with some NS5A inhibitors, such substitutions have 
limited impact in gt-1b infections (AASLD-IDSA; Zeuzem et al., 2017).
To better understand the evolutionary pathways leading to NS5A 
inhibitor resistance in gt-1a and gt-1b infection, we used next genera-
tion sequencing (NGS) with tagged cDNA primers (“primer ID sequen-
cing”) (Jabara et al., 2011; Zhou et al., 2015) to intensively characterize 
HCV diversity in small cohorts of gt-1a and gt-1b infected patients re-
ceiving a 5 day course of elbasvir monotherapy. Primer ID sequencing 
overcomes several limitations of conventional NGS by eliminating 
multiple types of PCR-related errors, thereby allowing unprecedented 
sequencing depth and accuracy (overall error rate ∼0.01%) (Jabara 
et al., 2011; Zhou et al., 2015). Each template consensus sequence 
(TCS) generated by primer ID sequencing represents an original viral 
RNA template queried at the very first cDNA synthesis step, making 
primer ID sequencing an excellent tool to study highly diversified viral 
populations such as HIV-1 and HCV (Barnard et al., 2016; Jabara et al., 
2014; Keys et al., 2015; Zhou et al., 2016). Coupling this approach with 
a unique set of serial serum samples collected before, during and after 
five days of elbasvir monotherapy, we show here that gt-1a and gt-1b 
HCV acquire antiviral resistance through distinct selection pathways, 
and that genotype-specific differences in RAS linkage and frequency can 
be linked to differences in cell culture assays of viral fitness.
2. Materials and methods
2.1. Study participants, clinical samples, and primer ID sequencing
Serial plasma samples were collected from subjects participating in 
a phase 1b clinical trial in which they received either elbasvir (10 mg or 
50 mg q.d.) monotherapy or placebo for 5 days (MK-8742 P002 trial, 
ClinicalTrials.gov Identifier: NCT01532973) (Liu et al., 2015). Seven 
subjects were infected with gt-1a HCV (4 receiving 50 mg of elbasvir, 2 
10 mg of elbasvir, and 1 placebo) and 6 subjects were infected with gt-
1b virus (5 receiving 50 mg elbasvir and 1 placebo). RNA encoding 
domain I of NS5A (amino acids 23–123) was sequenced in an average of 
6 serum samples from each subject, collected between 0 (pre-treatment) 
and 60 days after the initiation of therapy (Table S1). Primer ID li-
braries were constructed using previously published protocols and 
primer sequences shown in Table S2 (Zhou et al., 2015, 2016). Multi-
plexed libraries were sequenced using Illumina MiSeq (Illumina, San 
Diego, CA) 300 bp paired-end sequencing.
2.2. Bioinformatics and phylogenetic analysis
3.4. Evolutionary pathways to NS5A inhibitor resistance in gt-1a virus
Since primer ID sequencing retains information concerning linkage
between substitutions, subsequent analyses focused on the linkage be-
tween changes at codons 28, 30, 31, and 93, determining haplotypes
defined by these positions at each timepoint. As an example, Subject 2
was infected with gt-1a HCV and recieved 10mg elbasvir (Table S1). At
baseline the viral population was homogenous at all four codons, with
M28, Q30, L31 and Y93 (“MQLY” haplotype, Fig. 2A, top). By day 2, the
viral population had changed dramatically, consistent with a sub-
stantial, greater than 3.0 log10 drop in the level of viremia (Fig. 2A,
bottom). The original consensus MQLY haplotype had declined to only
14% of the population, and haplotypes with Y93H (MQLH) and L31M
(MQMY) dominated with frequencies of 41% and 23%, respectively.
Minor haplotypes included those with Q30R (MRLY), Q31H (MHLY)
Q30E (MELY), or M28T (TRLY), each at ∼5%.
These variants evolved throughout the 5-day treatment period and
continued to change in frequency after therapy with the emergence of
new haplotypes (Fig. 2A). Variants with Y93H were most abundant at
day 4 (79% MQLH), but quickly declined in frequency after cessation of
therapy (17% by day 12) and were largely absent by day 60. Y93N
(MQLN) represented 4% of the population at day 4, increased to 14% at
days 9 and 12, and similarly decreased to ∼1% by day 60. In contrast,
variants with substitutions at position 30 (MRLY, MELY, and MRMY)
began to increase in frequency off drug at day 6, becoming dominant as
the viremia rebounded to the baseline level. Variants with substitutions
at codon 31 (MQMY and MQVY) persisted at a frequency of 5–10% at
the end of the study. Thus, we documented two major pathways to drug
resistance in this subject: (1) Y93H/N/S/C, and (2) Q30R/E/H with or
without L31M, with less common pathways to resistance including
L31M/V, and M28T with or without Q30R. Temporal changes in the
relative frequencies of individual haplotypes on and off therapy were
likely driven by differences in degrees of elbasvir resistance and re-
plicative fitness. Importantly, we never observed Y93H and Q30R in the
same lineage.
Both of these major resistance pathways were observed in 5 of the 6
gt-1a subjects (Fig. 2A and Fig. S3). Subject 6, in whom Q30R was
dominant at baseline (98% MRLY), was an exception (Fig. 2B). This
subject experienced less than a 2 log10 drop in viremia by day 6 despite
treatment with 50mg elbasvir daily. The baseline MRLY haplotype
decreased in frequency during and off treatment, dropping to only 6%
by the end of the study. L31M/V substitutions began to emerge within
the background of Q30R on day 1, with an MRVY haplotype becoming
dominant at day 7, and increasing to 92% by day 60 when viremia was
greater than 10-fold that at baseline.
3.5. Evolutionary pathways of NS5A inhibitor resistance in gt-1b virus
In gt-1b infected subjects, we observed little or no change in hap-
lotype frequencies 4 h after starting elbasvir, but found viremia sup-
pressed so severely by day 1 that changes in the viral population could
not be assessed. Major changes were observed in rebounding virus
populations, however. For example, viral rebound was sufficient in
subject 8 by day 21 to determine that the baseline consensus LRLY
Fig. 1. Pre-treatment intra-host diversity in HCV
RNA encoding domain 1 of NS5A. (A) Baseline heat
map of amino acid substitutions at potential RAS
positions in domain I of NS5A in subjects with gt-1a
(subjects 1–7) and gt-1b (subjects 8–13) infections.
Positions analyzed include those identified by el-
basvir-induced changes in Shannon's entropy (see
Figs. S1 and S2). Frequencies of specific substitutions
are shown in different colors for each subject at each
position (see key at bottom). Highlighted positions
are major sites of RASs previously reported. Pos,
position; WT, wildtype; aa, amino acid. (B and C)
Distributions of TN93 distances of baseline HCV viral
populations in gt-1a (B) and gt-1b (C) subjects. The x-
axis is the TN93 distance (substitutions per site), the
y-axis shows the frequency of TN93 distance. Mul-
tiple peaks on the distribution plot suggests that the
viral population is comprised of multiple distinct
variants.
haplotype (100%) had been largely replaced by a haplotype with dual
Y93H and L31M substitutions (68% LRMH, Fig. 3A). MRLH, LRVH and
LRLH haplotypes were also present as minor variants. Unlike what we
observed in gt-1a infected subjects, gt-1b haplotypes with Y93H per-
sisted off therapy and remained dominant at the end of the study
(Fig. 3A). Resistant variants emerged in a similar fashion in subjects 9,
10 and 11 who were also infected with gt-1b virus (Fig. S3). In each,
Y93H was dominant in the rebounding viral population and persisted
with or without concomitant L31M/V or L28M substitutions, whereas
the baseline consensus haplotype was detectable but remained at a low
levels throughout follow-up.
Subject 12, who had a high frequency of Y93H at baseline (24%
LRLH), was an exception among the gt-1b subjects (Fig. 3B). The
baseline consensus haplotype, LRLY, was decreased in frequency by 4 h,
and present at very low frequency when viremia rebounded at 21 days.
Variants with an L31V substitution (LRVY) were dominant in the
rebounding virus population (Fig. 3B), but over time this haplotype was
partially replaced by an increasing frequency of Y93H variants (LRLH,
LRVH, and LRIH haplotypes) which persisted to the end of the study.
3.6. Genetic structure of HCV populations before and after elbasvir
treatment
We performed phylogenetic analyses to further examine the linkage
between RASs and the genetic structure of viral populations. Fig. 4
compares the phylogenetic trees of HCV in subjects with gt-1a and gt-1b
infections at baseline and following elbasvir treatment. In the 1a-in-
fected subject shown (subject 4, Fig. 4A), resistant variants with Y93H/
N substitutions can be seen to have arisen by day 7 in multiple in-
dependent lineages, some very closely related to baseline lineages.
Importantly, there were no lineages with both Y93H/N and Q30R
substitutions, consistent with the linkage analysis described above.
Fig. 2. Evolutionary pathways to elbasvir resistance in gt-1a-infected subjects. (A) gt-1a infected subject 2. (B) gt-1a-infected subject 6 with a dominant pre-
existing Q30R substitution. Haplotypes defined by sequence at amino acid positions 28, 30, 31 and 93 (see text) are shown at the bottom of each graph. Dashed lanes
indicate when the elbasvir monotherapy ended.
Fig. 3. Evolutionary pathways to elbasvir resistance in gt-1b-infected subjects. (A) gt-1b-infected subject 8. (B) gt-1b-infected subject 12, with a high-frequency
of pre-existing variants with a Y93H substitution. See legend to Fig. 2 for additional details.
Similar evolutionary patterns were observed in other gt-1a subjects
receiving elbasvir (Fig. S4). In contrast, in gt-1b-infected subjects (for
example subject 9, Fig. 4B), the viral population shifted completely
post-therapy as Y93H emerged and persisted in novel lineages, some
with additional substitutions on top of Y93H, such as L28M, L31V, and
L31M. With the exception of subject 12, phylogenetic patterns were
similar in the other gt-1b-infected subjects (Fig. S5). In contrast, po-
pulation structures were stable in placebo recipients (Figs. S6 and S7).
3.7. RAS impact on replicative fitness and drug susceptibility of gt-1a and
gt-1b virus
Both drug resistance and replicative fitness influence how viral
variants emerge and persist with antiviral therapy. To see whether in
vitro measurements of these parameters might explain the differences
we observed between gt1-1a and gt-1b-infected subjects, we used lu-
ciferase-expressing gt-1a (H77S.3/GLuc2A, MQLY haplotype) and gt-1b
(N.2/GLuc2A, LRLY) reporter viruses (Beard et al., 1999; Yamane et al.,
2014; Yi et al., 2006) (Fig. 5A). GLuc expression by these viruses pro-
vides a measure of their replication. Preliminary studies demonstrated
that the EC50 of elbasvir (determined 72 h after drug addition) was
lower for the gt-1a (2.2 pM) than the gt-1b reporter virus (7.1 pM). The
maximal inhibition achieved with concentrations of elbasvir ≥250 pM
was also greater for the gt-1a versus gt-1b virus at 48 (p < 0.0001 by
two-sided t-test) and 72 h (p=0.0033) after addition of drug (Fig. 5B).
Since NS5A inhibitors impede RNA replication by blocking assembly of
the replicase complex, this suggests a significantly shorter half-life for
the gt-1a replicase complex (Benzine et al., 2017; McGivern et al.,
2014). These findings are consistent with previously published work
indicating that elbasvir is at least as potent against gt-1a as gt -1b
viruses (Liu et al., 2015).
Although replicon studies indicate Y93H/N substitutions cause the
highest levels of elbasvir resistance in both gt-1a and gt-1b HCV, re-
ported fold-increases in EC50 were only 17 for gt-1b compared to
220–929 for gt-1a (Liu et al., 2015). The capacity of gt-1a virus to
sustain greater elbasvir resistance than gt-1b may thus have contributed
to higher levels of viremia during treatment in gt-1a than gt-1b infected
subjects. Y93H also caused a much greater loss of replicative fitness in
the gt-1a reporter virus: the gt-1a MQLH haplotype replicated at only
3% the level of the wild-type MQLY, whereas the gt-1b LRLH haplotype
was 41% as fit as LRLY (Fig. 5C). Replicon studies suggest other gt-1b
strains may be more negatively impacted by Y93H substitutions (Liu
et al., 2015), but these results are consistent with the persistence of gt-
1b and not gt-1a Y93H variants post-treatment (Figs. 2 and 3, and Fig.
Fig. 4. Phylogenetic trees of sequences obtained at 0 h and first available data point after the 5-day therapy. (A) gt-1a-infected subject 4, (B) gt-1b-infected
subject 9. Sequences in blue were obtained from the 0-h sample whereas those in red are from the 7-day sample and 21-day sample for subjects 4 and 9, respectively.
Haplotyes defined by amino acid residues at positions 28, 30, 31 and 93 are labeled with each major viral linage. Residues shown in black font represent baseline
(consensus sequence) whereas those in color are RASs.
Fig. 5. Impact of RASs on replicative fitness of gt-1a and gt-1b reporter
viruses. (A) Genome organization of gt-1a H77S.3/GLuc2A and gt-1b N.2/
GLuc2A reporter viruses that express Gaussia princeps luciferase (GLuc) from
sequence inserted upstream of the NS5A-coding region, between p7 and NS2
(Yamane et al., 2014). (B) Inhibition of GLuc secretion by cells infected with
(left) gt-1a H77S.3/GLuc2A or (right) N.2/GLuc2A viruses 20, 48 or 72 h after
the addition of elbasvir at the indicated concentrations. Results represent the
mean ± SEM of 3 technical replicates. (C) Huh7 cells were transfected with
genomic RNAs representing NS5A haplotypes indicated by the single letter-code
for the amino acid residues present at positions 28,30, 31 and 93, with genotype
consensus amino acid residues in black and RASs shown in red font. Secreted
GLuc activity was measured at 6, 24, 48 and 72hr post transfection, with results
normalized to activity at 6h (arbitrarily set to 1.0). Data shown represent the
mean ± S.E.M. of 3 independent experiments, each with 3 technical replicates.
ΔGDD is replication-incompetent H77S RNA carrying a lethal mutation in the
active site of the NS5B RNA-dependent RNA polymerase.
4. Discussion
While NS5A inhibitors are an important component of effective DAA
combination therapies for both gt-1a and gt-1b HCV infection, treat-
ment outcome is generally superior in gt-1b-infected persons (Lawitz
et al., 2012; Liu et al., 2015). This cannot be attributed to differences in
drug potency, as reflected in EC50 values, and the reasons for this dif-
ference remain uncertain. We show here that gt-1a and gt-1b viruses
differ fundamentally in the way in which resistant variants emerge and
persist off therapy, and that some of these differences correlate with
genotype-specific differences in the impact of RASs on resistance and
replicative fitness.
Our study is unique among others that have examined the response
of HCV to NS5A inhibitors. The use of primer ID sequencing eliminated
errors commonly introduced by PCR as well as sequencing platform
artifacts existing in conventional next generation sequencing strategies
(Jabara et al., 2011; Keys et al., 2015; Lee et al., 2017; Zhou et al.,
2015). It also allowed us to identify linkage between RASs. The method
was sufficiently sensitive to accurately detect minority variants with
frequencies as low as 0.03%–0.1% in the viral population (a function of
the number of viral genomes actually sequenced). The number of sub-
jects we studied was relatively small, and of necessity limited by the
intensity of the analysis. However, the changes we observed in HCV
populations during and after elbasvir therapy are likely representative
of those occurring generally in gt-1a and gt-1b infected patients, and
provide new insight into how resistance to NS5A inhibitors evolves.
In gt-1a infected subjects, we observed two major independent
pathways to resistance (Fig. 6). Y93H/C/N substitutions emerged
during treatment, but rapidly diminished in frequency off therapy,
becoming minor variants 2 months later. Q30R and L31M/V substitu-
tions were also observed early in treatment, but these RASs, either in-
dividually or in combination, increased in frequency following cessa-
tion of therapy. The dominance of Y93H during treatment may be
explained by its far greater resistance to elbasvir (220-fold increase in
EC50) compared to Q30R (16-fold) (Liu et al., 2015) (Table S3). On the
other hand, the much greater replicative fitness of Q30R versus Y93H
(Fig. 5C) explains the expansion of Q30R genomes off treatment
(Fig. 6). Moreover, in vitro data show that second-site L31M substitu-
tions fully rescue the fitness of virus with Q30R (Fig. 5C), contributing
to Q30R persistence and dramatically boosting elbasvir resistance
(Table S3). Interestingly, while we detected Q30R at baseline in all 7 gt-
1a infected subjects (Fig. 1A), it was dominant in only one (subject 6,
Fig. 2B). A review of the Los Alamos database found Q30R present in
only 13 of 3018 (0.4%) gt-1a sequences.
In contrast to gt-1a infected subjects, we observed only a single
pathway to resistance in those with gt-1b infection (Fig. 6). Viremia was
extremely low during elbasvir treatment of these subjects. The effective
size of the replicating viral population is thus likely to have been much
smaller in the gt-1b than gt-1a subjects during therapy, most likely
because even the most resistant Y93H and L31F gt-1b variants de-
monstrate only 15- to 17-fold increases in EC50 (Liu et al., 2015). In
contrast to gt-1b infected subjects, where rebounding resistant virus
populations demonstrated fundamentally altered structures, RASs
emerged from multiple preexisting viral linages in gt-1a subjects
(Fig. 4A and Fig. S6). This suggests that the effective population size on
therapy was sufficiently large in these patients to allow for the de-
terministic selection of RASs. All possible RASs are likely to have been
present before the treatment due to the error-prone nature of HCV RNA
synthesis, emerging with drug selection pressure when replication is not
fully suppressed. In gt-1b, the limited effective population size during
therapy may have allowed only the most resistant variants (Y93H
pathway) to be selected.
Unfortunately, available crystallographic models of NS5A structure
provide little insight into why the evolution of inhibitor resistance
differs in gt-1a and gt-1b viruses. There are several domain I structures
reported, but none include the amino-terminal 35 amino acids, and thus
we do not know how 3 critical residues (positions 28, 30 and 31) are
positioned within the molecule. Moreover, models of the gt-1a
(Lambert et al., 2014) and gt-1b (Tellinghuisen et al., 2005) structures
differ in that gt-1b is a dimer, while gt-1a is a tetramer, with the relative
positioning of the monomer subunits different in each. It is not clear
which of these models reflects the native conformation of NS5A, and it
is possible that the molecule adopts both folds. A complete molecular
explanation for the findings we describe here must thus await a better
understanding of the NS5A structure and its association with other
components of the HCV replication complex.
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Fig. 6. Major evolutionary pathways to NS5A resistance in subjects in-
fected with gt-1a and gt-1b HCV infection. Changes in the NS5A domain I
sequence of gt-1a and gt-1b virus are shown in overlapping or independent
Venn diagrams during and after treatment with elbasvir according to the single
letter amino acid code for residues at positions 28, 30, 31, and 93. The size of
each circle is roughly proportionate to their frequencies in the viral population.
The emergence and persistence of variants is driven by positive selective forces
related to the magnitude of drug resistance during therapy, and relative re-
plicative fitness subsequently. Note that gt-1a virus has two distinct pathways
to resistance, while only one was observed in gt-1b infections.
S3).
Similar studies help to explain the second-site L31M/V substitutions 
we observed in gt-1a subjects with Q30R (Fig. 2 and Fig. S5). Q30R 
causes a 16-fold increase in the EC50 of gt-1a replicons (Liu et al., 
2015), and this substitution was frequent in the gt-1a subjects we stu-
died (Fig. 2 and Fig. S5). However, as noted above, Q30R and Y93H/N 
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